Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma by Oliva, S. et al.
MINI REVIEW
published: 31 January 2020
doi: 10.3389/fonc.2020.00001
Frontiers in Oncology | www.frontiersin.org 1 January 2020 | Volume 10 | Article 1
Edited by:
Francesco Maura,
Memorial Sloan Kettering Cancer
Center, United States
Reviewed by:
Cirino Botta,
Cosenza Hospital, Italy
Matteo Claudio Da Vià,
University of Milan, Italy
Dickran Kazandjian,
National Cancer Institute, National
Institutes of Health (NIH),
United States
*Correspondence:
Alessandra Larocca
alelarocca@hotmail.com
†These authors have contributed
equally to this work and share first
authorship
Specialty section:
This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology
Received: 29 October 2019
Accepted: 02 January 2020
Published: 31 January 2020
Citation:
Oliva S, D’Agostino M, Boccadoro M
and Larocca A (2020) Clinical
Applications and Future Directions of
Minimal Residual Disease Testing in
Multiple Myeloma. Front. Oncol. 10:1.
doi: 10.3389/fonc.2020.00001
Clinical Applications and Future
Directions of Minimal Residual
Disease Testing in Multiple Myeloma
Stefania Oliva †, Mattia D’Agostino †, Mario Boccadoro and Alessandra Larocca*
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Cittá Della Salute e Della
Scienza di Torino, Turin, Italy
In the last years, the life expectancy of multiple myeloma (MM) patients has substantially
improved thanks to the availability of many new drugs. Our ability to induce deep
responses has improved as well, and the treatment goal in patients tolerating treatment
moved from the delay of progression to the induction of the deepest possible response.
As a result of these advances, a great scientific effort has beenmade to redefine response
monitoring, resulting in the development and validation of high-sensitivity techniques
to detect minimal residual disease (MRD). In 2016, the International Myeloma Working
Group (IMWG) updated MM response categories defining MRD-negative responses both
in the bone marrow (assessed by next-generation flow cytometry or next-generation
sequencing) and outside the bone marrow. MRD is an important factor independently
predicting prognosis during MM treatment. Moreover, using novel combination therapies,
MRD-negative status can be achieved in a fairly high percentage of patients. However,
many questions regarding the clinical use of MRD status remain unanswered. MRD
monitoring can guide treatment intensity, although well-designed clinical trials are needed
to demonstrate this potential. This mini-review will focus on currently available techniques
and data on MRD testing and their potential future applications.
Keywords: multiple myeloma (MM), minimal residual disease (MRD), clinical practice, next-generation flow (NGF),
next-generation sequencing (NGS), PET/CT
INTRODUCTION
The treatment course of multiple myeloma (MM) has been strongly improved during the last
20 years: the introduction of modern 3-drug regimen therapies combined with transplantation
increased the achievement of deeper responses and the acquisition of minimal residual disease
(MRD) negativity in up to 40/50% of patients enrolled in clinical trials (1). Consistently, a large
number of studies showed that, among patients achieving a complete response (CR), those with
detectable MRD had inferior progression-free survival (PFS), and overall survival (OS) compared
to those with undetectable MRD. Moreover, among patients in CR, improved PFS and OS have
been significantly associated with undetectable MRD, regardless of disease stage, prior transplant,
or cytogenetic risk (2).
Therefore, the International Myeloma Working Group (IMWG) recently revised the response
criteria and introduced the definition of MRD in CR patients as the persistence or re-emergence
of very low levels of cancer cells, equal to about 1 tumor cell in at least 105 normal cells (3). These
response criteria are the direct result of the progressive evolution of both imaging and bonemarrow
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FIGURE 1 | Timeline on the development and validation of MRD techniques in MM. MRD, minimal residual disease; MM, multiple myeloma; CR, complete response;
sCR, stringent CR; IMWG, International Myeloma Working Group; ASO-PCR, allele-specific oligonucleotide polymerase chain reaction; NGS, next-generation
sequencing; 18-FDG PET/CT, 18-fluorodeoxyglucose positron emission tomography/computed tomography; ClonoSEQ®, ClonoSEQ® Assay (Adaptive
Biotechnologies, Seattle, US-WA); FDA, Food and Drug Administration.
TABLE 1 | Bone marrow techniques for MRD in myeloma: pros and cons.
Next-generation flow
(NGF)
Next-generation sequencing
(NGS)
Applicability Nearly 100% ≥90%
Availability Many laboratories with
4–6 colors; >8 colors
restricted to more
specialized centers
Commercial service only;
ongoing efforts by academic
platforms
Diagnostic sample Not required Required for identification of
dominant clonotype
Number of cells
required
10 million cells/tube 1–2 million cells/20 µg DNA
Sample
processing
Requires a fresh
sample; assessment
within 24–48 h
Can use both fresh and stored
samples
Standardization EuroFlow consortium Commercial companies
(Adaptive Biothcnologies)
Academic methodologies also
available
Sample quality
control
Possible to check by
global bone marrow
cell analysis
Not possible
Quantitative Yes Yes
Sensitivity 1 in 10−5-10−6 1 in 10−5-10−6
Turnaround and
complexity
3–4 h. Requires flow
cytometry skills.
Automated software
available
1 week. Academic
methodologies require
bioinformatics support
Clonal evolution Not evaluable Evaluable: can take into account
all minor clones
MRD, minimal residual disease.
MRD techniques in the last 15 years (Figure 1). However, a
precise knowledge of when and how to perform MRD detection
is required. This review aims to examine the currently available
MRD techniques recommended by IMWG and data from
different clinical trials, in order to outline a possible future
perspective on the role of MRD testing as a tool for decision
making in standard clinical practice.
MRD TECHNIQUES AND PRACTICAL
CONSIDERATIONS
Bone Marrow Techniques: NGF and NGS
There are two techniques commonly used to detect MRD in the
bone marrow (BM): multiparameter flow cytometry (MFC) and
next-generation sequencing (NGS) molecular technology. Both
techniques show positive and negative aspects (Table 1).
MFC can detect and quantify tumor vs. normal plasma cells
using cell surface and cytoplasmic markers. For the identification
of plasma cells, the combined use of CD38 and CD138 is
recommended even if they are also expressed on other BM cells.
In particular, the aberrant expression patterns of CD19, CD56,
CD45, CD38, CD27, CD20, CD28, CD33, CD117 and surface
membrane immunoglobulin can characterize the phenotype of
monoclonal plasma cells (4). However, antigenic expression can
vary on plasma cells and should be considered when interpreting
flow data.
Older conventional 4- to 7-color flow cytometry assays have
now been replaced by advanced 8-color 2-tube or 10-color 1-tube
assays. In this sense, the increased sensitivity of MFC (between
10−4 and 10−5) is due to the simultaneous assessment of ≥8
markers in a single tube. In this way, if sufficient cell numbers
are evaluated (e.g., ≥5 × 106), it is possible to promptly identify
aberrant PC phenotypes at MRD levels (5).
A consensus methodology has been recently proposed by
the International Myeloma Foundation’s Black Swan Research
Initiative, which formed the EuroFlow Next-Generation Flow
(NGF) panel in order to increase sensitivity and standardization
of MFC (6, 7). This panel includes two 8-color tubes (tube
1: CD138, CD27, CD38, CD56, CD45, CD19, CD117, CD81;
tube 2: CD138, CD27, CD38, CD56, CD45, CD19, cIgκ,
cIgλ). In this protocol, a bulk-lysis procedure was determined
and the acquisition of ≥107 cells/sample was recommended.
Importantly, new softwares were developed for automatic plasma
cell gating in order to avoid individual assessments.
According to this consensus methodology, it is important
to evaluate the limit of quantitation (LOQ) and the limit
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of detection (LOD) of the NGF-MRD method. The LOQ is
calculated as 50 among 107 nucleated cells (based on the
identification of ≥50 clonal plasma cells); the LOD as 20 among
107 nucleated cells (based on the identification of ≥20 clonal
plasma cells). This evaluation allows to discriminate between
positive and negative samples. Interestingly, a baseline sample
is not mandatory for MRD evaluation. After the multicenter
evaluation of patients with very good partial response (VGPR)
or CR, 110 follow-up bone marrows showed a higher sensitivity
for NGF-MRD, as compared to conventional 8-color flow-MRD:
MRD-positive rates were 47 vs. 34% (P = 0.003), respectively.
Thus, 25% of patients who were categorized as MRD-negative
by conventional 8-color flow were categorized as MRD-positive
by NGF. This translated into a significantly longer PFS using
NGF to discriminate between MRD-negative and MRD-positive
CR patients (P = 0.02). Importantly, NGF can also provide
a qualitative assessment of the patient sample by allowing
the complete analysis of the normal B-cell compartment and
the detection of a significantly decreased number of non-PC
BM cells (e.g., mast cells, nucleated red blood cells, myeloid
precursors, B-cell precursors, and CD19– normal PC) revealing
potentially hemodiluted BM samples. Finally, treatment with
CD38 antibodies such as daratumumab and isatuximab can alter
the antigen expression in MM cells. This sets a limit for the use
of CD38 as a marker for the detection of plasma cells during
MRD assessments at follow-up. The use of multi-epitope CD38
antibody in an advanced flow cytometry panel can solve this
problem, since this conjugate can bind to a specific site (not
covered by daratumumab) of the CD38 antigen. Nonetheless,
in case of CD38 surface downregulation, the solution is the
analysis of intracellular CD38 through the same protocol used
for intracellular k- and λ-chain staining (7).
Allele-specific oligonucleotide polymerase chain reaction
(ASO-PCR) was first explored to evaluate molecular MRD in
MM, but even if its prognostic role was confirmed, different
issues limited its use in favor of the NGS technique. First, its
applicability ranged from 40 to 60% due to the low rate of
diagnostic marker identification, since this technique does
not take into account the somatic hypermutation rate of
immunoglobulin loci and this translates into sequencing
problems. Moreover, patient-specific reagents raised the
complexity of this technique (8–11).
NGS was developed to overcome all these disadvantages.
ClonoSEQ R© Assay (Adaptive Biotechnologies, Seattle, US-WA)
is the most frequently adopted commercial platform in the
United States. In this test, DNA is extracted from patient’s
BM, a multiplex PCR amplifies VDJ, IgK, and IgL gene
sequences and a common PCR prepares DNA for sequencing
and creates a sequencing library. At the end of the process,
a bioinformatic tool is essential to extrapolate and analyze all
NGS data.
Using this assay, we can define as “clonotypes” two identical
sequencing reads. A clonotype with frequency >5% at diagnosis
is considered a clonality (clonal gene rearrangements), thus
becoming a target for the detection of MRD in follow-up samples
(12, 13). In lymphoid malignancies, NGS and ASO-PCR have
been compared, showing similar sensitivities and results (13).
In the IFM2009 clinical trial, a comparison between NGS and
7-color MFC has been made, showing that the higher sensitivity
with NGS at 10−6 allowed to predict the best outcomes in MRD-
positive vs. -negative patients (3-year PFS: 53 vs. 83%, p< 0.001).
Ongoing clinical trials are evaluating NGS vs. NGF and their
correlation: in the CASSIOPEIA trial, a good concordance (83.5%
in paired samples) was observed using the same sensitivity (10−5)
regardless of response in patients achieving ≥CR, indicating
that both techniques performed similarly in evaluating MRD
(14). As illustrated in Table 1, some characteristics can affect
the clinician’s preference of choosing NGS vs. NGF, such as the
higher cost for NGS (∼1,500 $ per sample vs. ∼300 $ for NGF),
and the required time and skills (at least 1 week for NGS vs. 3–4 h
for NGF and commercial service available only for NGS).
In this regard, ongoing studies are evaluating ‘in-house’ NGS
techniques: recently, Martinez-Lopez et al. described a NGS
method starting from 1 µg of DNA and amplified IGH or
IGK sequences. The sequencing data were analyzed by specific
mathematical and bioinformatic tools to identify and quantify
the clonotype present on each sample. A clonotype was identified
when at least 400 identical sequencing reads were obtained, or
when it was present at a frequency of >1% with a sensitivity of at
least 10−5 (15).
Imaging Techniques: PET/CT
MM is a patchy disease and BM infiltration may often be
heterogeneous. Indeed,∼60% of MM patients show focal lesions
that represent the local accumulation of plasma cells (16).
Therefore, the IMWG incorporated imaging in addition to BM
evaluation to better characterize MM residual disease (3).
Different studies showed the role of imaging techniques in
evaluating focal lesions: magnetic resonance imaging (MRI) is a
sensitive, non-invasive imaging technique available to detect the
bone involvement in the spine and to provide details regarding
the soft tissue disease and the pattern of marrow infiltration
(normal, focal, diffuse, or heterogeneous).
Fluorodeoxyglucose positron emission
tomography/computed tomography (FDG PET/CT) can be
used to analyze the vitality of the focal lesions and is therefore the
current standard of care to evaluate the post-therapeutic residual
infiltration (17–19).
Different studies showed the prognostic and predictive role
of FDG PET/CT (20–22). Interestingly, Moreau et al. compared
PET/CT with MRI. Although at diagnosis both the techniques
performed similarly in the detection of bone lesions, the
normalization after therapy of PET/CT, but not of MRI, was
predictive of PFS and OS (20). In both responding and non-
responding patients, focal lesions can still remain positive
for many months. As a consequence, conventional MRI is
probably not the best technique to evaluate MRD (22–24).
On the other hand, functional MRI techniques based on the
measurement of the movement of water molecules in the tissue
(Diffusion-Weighted MRI, DWI) could be informative on the
residual cellularity and the microcirculation of the focal lesions
(25). No standardization of the diagnostic technique and no
interpretation of results in MM after therapy are still available
and no prospective comparison between PET/CT and DWI in
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a meaningful number of patients has been done. In a small
number of MM patients, DWI seemed to be more sensitive in
the detection of residual lesions. However, if this could be an
advantage or could lead to an increased number of false-positive
cases, still needs to be elucidated (26, 27).
Finally, different researchers confirmed the complementarity
of PET/CT and BM techniques. Rasche et al. showed how patients
who were both Flow-MRD- and PET/CT-negative had the best
PFS outcome when compared with those who were Flow-MRD-
negative but PET/CT-positive (28). Paiva et al. demonstrated
that, even if NGF-negative patients had a long PFS, there was a
proportion of subjects who relapsed with extramedullary disease
in the presence of a previous negative BM sample, confirming the
importance of combining BM and imaging analyses (29).
PET/CT has some limitations, some of which are linked
to the tracer used (FDG). Indeed, a low expression of the
enzymes responsible for the glycolysis process (e.g., hexokinase
2 gene) in MM cells could lead to false-negative cases with
FDG PET/CT (30). Alternative tracers could overcome these
limitations. For instance, 11C-Methionine uptake correlates with
protein synthesis, a very active mechanism in malignant plasma
cells, and can be used as an alternative PET/CT tracer in
MM (31).
In a head-to-head prospective comparison in a heterogeneous
MM patient population, 11C-Methionine PET/CT was more
sensitive than FDG PET/CT in the detection of focal lesions,
both within and outside the bone. More data are needed in
a homogenous patient population to understand whether this
tracer could be an alternative to FDG in the detection of residual
disease after treatment. Currently, other tracers targeting lipid
membrane (e.g., Choline, Acetate) and CXCR4 are also under
study (32).
MRD RESULTS IN THE CLINICAL SETTING:
RELEVANT QUESTIONS
In this section we focus on clinically relevant questions regarding
MRD, reviewing available data on newly diagnosed MM
(NDMM) patients. Single studies are summarized in Table 2.
Data on MRD evaluation in relapsed and/or refractory MM
patients (59) and high-risk smoldering MM (60) are beginning to
emerge as well, and have been recently reviewed elsewhere (61).
In the MM field, a major question concerned the prognostic
role of MRD and its ability to perform better than conventionally
defined response criteria. As already discussed, there is now
compelling evidence coming from multiple studies (Table 2)
and two meta-analyses (2, 62) confirming that MRD-negative
patients have a significantly better PFS and OS compared to
MRD-positive patients. The beneficial effect of MRD negativity
was confirmed also focusing on CR patients (2). Using MFC with
a sensitivity of 10−4-10−5, Lahuerta et al. nicely demonstrated
that MRD-negative patients with a conventionally defined CR
had better PFS (median, 63 vs. 27 months, p < 0.001) and OS
(median, not reached vs. 59 months, p < 0.001) than MRD-
positive CR patients (42). Moreover, MRD-positive CR patients
had similar outcomes compared to patients achieving a partial
response (PR) (median PFS, 27 vs. 29 months; median OS, 59 vs.
65 months, respectively) showing that the prognostic advantage
of conventionally defined CR over PR resided in the MRD-
negative patient population (42).
The best timing for MRD measurement is another important
unanswered question. Usually, MRD is measured at specific
timepoints during therapy [e.g., post-induction (39), +100 days
post-ASCT (33), post-consolidation (41), pre-maintenance, and
during maintenance (46)]. If treatment does not provide for
a phase-specific timepoint (as in the case of the continuous
treatment strategy commonly adopted for transplant-ineligible
patients), MRD testing is usually done at unconfirmed CR/sCR
and at fixed timepoints thereafter (50).
Data clearly show that, as we continue to intensify patient
treatment, the percentage of MRD-negative patients increases
(39, 43, 53, 55, 56) and even maintenance treatment can convert
a significant percentage of MRD-positive patients into MRD-
negative [e.g., 27–30% with lenalidomide maintenance in a
pooled analysis (9, 46)]. Each timepoint can be important due
to different clinical reasons. For instance, the post-induction
timepoint can be used to design clinical trials addressing
different intensification regimens, while pre-maintenance or
during maintenance timepoints can be exploited to design clinical
trials addressing the intensity and the duration of maintenance.
Regarding the prognostic effect of different timepoints, in the
Myeloma IX study, which used MFC with a sensitivity of
10−4, a PFS advantage was found in patients that were MRD-
negative both post-induction and post-ASCT, as compared with
patients that were MRD-positive post-induction and became
MRD-negative post-ASCT, although this effect did not translate
into an OS benefit (34). On the other hand, Hahn et al.
demonstrated in a transplant-eligible population that patients
who were MRD-negative pre-ASCT, pre-maintenance, and 1-year
post-ASCT showed all a better PFS compared to MRD-positive
patients. Only the 1-year post-ASCT timepoint was associated
with better OS (3-year post-ASCT OS 96 vs. 66% for MRD-
negative vs. MRD-positive patients) (53). These data suggest that
the duration of MRD negativity may be important, but little
data are available on sustained MRD negativity (i.e., the need
to confirm MRD at different timepoints) and on its optimal
duration. Gu et al. used MFC to monitor 104MM patients
post-induction and at different post-ASCT timepoints (3 to 24
months), showing that patients with persistent MRD negativity
post-induction until 24 months after ASCT (n = 33) had better
time to progression (median, not reached vs. 15.4months) and
OS (not reached vs. 35.2 months), as compared to patients that
were MRD-negative post-induction but MRD-positive within 24
months post-ASCT (n = 5) (43). The low numbers in the latter
group do not allow the exploration of different time cutoffs for
sustained MRD negativity. However, 2/5 patients became MRD-
positive 18 months post-ASCT, thus suggesting that long-term
confirmation of sustained MRD negativity may be necessary.
Another question is whether the sensibility of the technique
impacts the reliability of MRD. Using MFC with a sensibility
of 10−4, Rawstron et al. demonstrated that each log depletion
in MRD levels predicted a 1-year median OS advantage (5.9
years for 10−2-10−3, 6.8 years for 10−3-10−4, and more than 7.5
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TABLE 2 | Selected trials on NDMM patients reporting MRD data.
Study Patient populationa (n) Method (sensitivity) Timepoint MRD-negativeb (%) Outcomes (MRD neg vs. MRD pos)
Paiva et al.
(33)
TE NDMM in ≥PR after 6 alternating VBMCP/VBAD cycles and
ASCT (295)
MFC (10−4 ) +100 days after ASCT 42% Median PFS: 71 vs. 38 months
Rawstron
et al. (34)
NDMM:
- Intensive arm (378): CTD (178) or CVAD (190) induction +
ASCT.
- Non–intensive arm (245): MP (119) or aCTD (126).
MFC (10−4 ) Post-induction (both arms)
and +100 days after ASCT
(intensive arm only)
Intensive arm:
Post CTd induction 25%
(71% post-ASCT)
Post CVAD 13% (54% post-ASCT)
Non-intensive arm:
Post MP induction 3%
Post aCTd induction 26%
Intensive arm:
Median PFS* according to post-ASCT
timepoint 29 vs. 16 months
Non-intensive arm:
Median PFS* according to post-induction
timepoint 10.5 vs. 7.4 months
Puig et al.
(10)
NDMM in ≥PR (102) ASO-PCR (10−4 ) Post-induction (NTE
patients) or +100 days after
ASCT (TE patients)
46% TE patients:
median PFS 54 vs. 27 months
NTE patients:
median PFS NR vs. 31 months
Kumar et al.
(35)
NDMM receiving IRd induction + ixazomib maintenance (64) MFC (10−4 ) Mostly at suspected CR 12.5% NA
de Tute at al.
(36)
NTE NDMM after aCTD or aRCD induction (297) MFC (10−4 ) Post-induction aCTD arm: 11%
aRCD arm: 16%
aCTD arm: median PFS 34 vs. 19 months
aRCD arm: median PFS 32 vs. 17 months
Ludwig et al.
(37)
TE NDMM in CR after 4 cycles of VTd or
VTd+cyclophosphamide induction and ASCT (42)
MFC (not specified) Suspected CR 81% Median PFS NR vs. 39 months
Paiva et al.
(38)
NTE NDMM in ≥PR after 6 VMP (52) or VTP (50) induction
cycles
MFC (10−4-10−5 ) Post-induction 30% 3-year PFS: 90% vs. NR
Roussel
et al. (39)
TE NDMM after 3 VRd + ASCT + 2 VRd cycles followed by
lenalidomide maintenance (31)
MFC (10−4-10−5 ) Longitudinal Post-induction: 16%
Post-ASCT: 54%
Post-consolidation: 58%
Post-maintenance: 68%
3-year PFS according to post-maintenance
MRD: 100% vs. 23%
Paiva et al.
(40)
TE NDMM in ≥CR after ASCT (241) MFC (10−4-10−5 ) +100 days after ASCT 64% 3-year TTP: 76% vs. 58%
Ferrero et al.
(41)
TE NDMM in ≥VGPR after ASCT (39) undergoing VTd
consolidation
ASO-PCR (10−4-10−5 ) Longitudinal Post-ASCT: 23%, Post-consolidation: 57%
6-month post-consolidation: 72%
Median PFS: 68 vs. 23 months
Korthals
et al. (11)
TE NDMM after 2–4 cycles of idarubicin-dexamethasone
undergoing ASCT
ASO-PCR (10−4-10−5 ) Post-induction and
post-ASCT (+3–6 months)
Post-induction: 17%
Post-ASCT: 21%
NA
Lahuerta
et al. (42)
NDMM alive and with MRD data available at 9 months after
treatment start (609)
MFC (10−4-10−5 ) 9 months after treatment
start
43% Median PFS* 63 months vs. NA (11–29
months in the other response categories)
Gu et al. (43) TE NDMM (101) MFC (50−4-10−5 ) Longitudinal Post-induction: 37%
Post-ASCT: 66%
2-year post-ASCT: 78%
Median TTP: NR vs. NR
Korde et al.
(44)
NDMM receiving 8 KRd induction cycles (45) NGS (not specified) Post-induction 42% (calculated on NGS-evaluable NDMM
patients)
18-month PFS: 100% vs. 84%
Martin-
Lopez et al.
(45)
NDMM in ≥VGPR (121) NGS [10−5 ] Post-induction (NTE
patients) or +100 days after
ASCT (TE patients)
27% Median TTP: 80 vs. 31 months
Oliva et al.
(46)
TE NDMM in ≥VGPR after consolidation (73) followed by
lenalidomide maintenance
ASO-PCR (10−5 ) Pre-maintenance and during
maintenance
Pre-maintenance: 45%
During maintenance: 60%
Median PFS: NR vs. 48 months
Oliva et al.
(47)
TE NDMM in ≥VGPR after
VCd induction, VMP vs. ASCT intensification, VRd vs. no
consolidation (316) followed by lenalidomide maintenance
MFC (10−5 ) Pre-maintenance and during
maintenance
Post-consolidation: 76% 3-year PFS*: 77% vs. 50%
Paiva et al.
(48)
NTE NDMM with response (80% of the patients with ≥VGPR)
after 18 sequential or alternating VMP/Rd cycles (162)
MFC (10−5 ) After 9 cycles or 18 cycles Sequential arm
9-cycles: 20%
18-cycles: 46%
Alternating arm
9-cycles: 19%
18-cycles: 33%
Median TTP*: NR vs. 15 months
(Continued)
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TABLE 2 | Continued
Study Patient populationa (n) Method (sensitivity) Timepoint MRD-negativeb (%) Outcomes (MRD neg vs. MRD pos)
Mateos et al.
(49)
NTE NDMM:
DaraVMp arm (350)
- VMp arm (356)
NGS (10−5 ) Longitudinal - Dara-VMp arm: 22.3%
- VMp arm: 6.2%
NA
Facon et al.
(50)
NTE NDMM:
- DaraRd arm (368)
- Rd arm (369)
NGS (10−5 ) Longitudinal Dara-Rd: 24.2%
Rd arm: 7.3%
NA
Voorhees
et al. (51)
TE NDMM receiving Dara-VRd induction, ASCT and Dara-VRd
consolidation (13)
NGS (10−5 ) Longitudinal Post-induction: 19%
Post-consolidation: 50%
NA
Gay et al.
(52)
TE NDMM receiving KCd-ASCT-KCd (arm A, 159),
KRd-ASCT-KRd (arm B, 158), 12 cycles of KRd (arm C, 157)
MFC (10−5 ) Pre-maintenance Arm A: 42%
Arm B: 58%
Arm C: 54%
NA
Flores-
Montero
et al. (7)
NDMM or RRMM patients achieving ≥VGPR (79) NGF (10−5-10−6 ) Post-induction, during
maintenance or
post-treatment
47% Time to 75% PFS event*: NR vs. 10 months
Hahn et al.
(53)
NDMM receiving induction and ASCT ± VRd consolidation
(293) followed by lenalidomide maintenance
MFC (10−5-10−6 ) Longitudinal Pre-ASCT 42%
Post-ASCT ± consolidation 78%
1 year post-ASCT 84%
Pre-ASCT 3-year PFS*: 69% vs. 60%
Post-ASCT ± consolidation 3-year PFS*: 75
vs. 59%
1-year post-ASCT 3-year PFS*: 76%
vs. 44%
Ocio et al.
(54)
NTE NDMM receiving Isa-VRd induction + Isa-Rd maintenance
(16)
NGF (10−5 ) and
NGS (10−5 )
Longitudinal NGF 44% (18% at 10−6 )
NGS 50% (33% at 10−6 )
NA
Zimmermann
et al. (55)
TE NDMM receiving 4 cycles of KRd induction-ASCT-4 cycles
of KRd consolidation and 10 cycles of KRd extended
consolidation (76)
MFC (10−4-10−5 ) and
NGS (10−6 )
Longitudinal MFC
Post-consolidation (cycle 8) 82%
Post-extended consolidation (cycle 18) 90%
NGS
Post-consolidation (cycle 8) 66%
Post-extended consolidation (cycle 18) 71%
According to cycle 8 MRD status by MFC
and/or NGS
2-year PFS: 100 vs. 93%
Avet-Loiseau
et al. (56)
NDMM receiving DaraVTd-ASCT-DaraVTd (543) or
VTd-ASCT-VTd (542)
MFC (10−5 ) and NGS
(10−6 )
Post-induction
Post-consolidation
Post-induction (MFC)
Dara-VTd arm: 35%
VTd arm 23%
Post-consolidation (MFC)
Dara-VTd arm: 64%
VTd arm 44%
Post-consolidation (NGS in evaluable
patients)
Dara-VTd arm: 39%
VTd arm 23%
NA
Takamatsu
et al. (57)
NDMM in ≥VGPR after ASCT (51) NGS (10−6 ) Post-ASCT (day 24–2,808) 51% 4-year PFS: 96% vs. NR
Perrot et al.
(58)
TE NDMM after 8 VRd cycles or 3 VRd + ASCT + 2 VRd
cycles followed by lenalidomide maintenance (509)
NGS (10−6 ) Pre- or post-maintenance VRd alone arm: 20%
ASCT arm: 30%
Median PFS: NR vs. 29 months
a If data come from a heterogeneously treated population, information about treatment is not showed. If data come from a single randomized trial, treatment data are provided.
b If data at different sensitivity levels are available, the MRD rates at highest sensitivity levels are provided.
*time-to-event calculated from MRD assessment.
NDMM, newly diagnosed multiple myeloma; MRD, minimal residual disease; CR, complete response; VGPR, very good partial response; MFC, multiparametric flow cytometry; ASCT, autologous stem-cell transplantation; TTP,
time-to-progression; PFS, progression-free survival; ASO-PCR, allele-specific oligonucleotide polymerase chain reaction; TE, transplant-eligible; NGS, next-generation sequencing; NR, not reached; NA, not available; NTE, transplant-
ineligible; Dara, daratumumab; Ixa, ixazomib; Rd, lenalidomide, dexamethasone; VRd, bortezomib, lenalidomide, dexamethasone; IRd, ixazomib, lenalidomide, dexamethasone; VTd, bortezomib, thalidomide, dexamethasone; VMP,
bortezomib, melphalan, prednisone; VCd; bortezomib, cyclophosphamide, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; KCd, carfilzomib, cyclophosphamide, dexamethasone; CRd, cyclophosphamide, lenalidomide,
dexamethasone; PR, partial response; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide, prednisone; VBAD, vincristine, carmustine, adriamycin, dexamethasone; CTD, cyclophosphamide, thalidomide, dexamethasone;
RCD, lenalidomide, cyclophosphamide, dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; MP, melphalan and prednisolone; aCTD/aRCD, attenuated CTD/RCD; NGF, next-generation flow.
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years for 10−4), suggesting that MRD level is a continuous rather
than a discrete variable (63). Recently, several studies using both
flow cytometry-based methods with a sensitivity of 10−5 (48) or
10−5-10−6 (7) and NGS-based methods with a sensitivity of 10−6
(58, 64) demonstrated that lower levels of MRD are associated
with better outcomes and that the best possible sensitivity should
be pursued. Indeed, in the IFM/DFCI 2009 trial, among 163
patients who were MRD-negative pre-maintenance using MFC
with a sensibility of 10−4, 84 (56%) were indeed MRD-positive
using NGS with a sensibility of 10−6 (3-year PFS, 86 vs. 66% in
NGS-negative vs. NGS-positive among MFC-negative patients).
This is especially important in clinical trials designed to explore
treatment interruption based on MRD levels because a low
sensibility of the technique can lead to unacceptable risk of
patients’ undertreatment.
This observation leads to our last question: if MRD negativity
is a major prognostic determinant, do treatment administered
and baseline risk stratification matter as long as MRD negativity
is achieved? Many studies demonstrated that even if a more
effective regimen induced MRD negativity in a higher number
of patients, the prognosis of MRD-negative patients was similar
independently from treatment arm (49, 58). However, we do
need MRD-driven clinical trials to determine if treatment
deintensification in MRD-negative patients is feasible without
worsening patient prognosis (65). In this regard, in the Myeloma
IX trial, MRD-negative patients (MFC at 10−4) receiving
thalidomide maintenance remained in a MRD-negative state
more often than patients not receiving maintenance treatment
(96 vs. 68.8%, p = 0.026). Regarding MM patients who are at
high risk according to baseline prognostic factors (e.g., high-
risk cytogenetics or unfavorable Revised International Staging
System score), MRD-negative patients at a low level of sensitivity
(10−4) still showed inferior clinical outcomes than standard-
risk patients (34). Conversely, reaching MRD negativity at
a sensitivity of 10−5-10−6 seemed to overcome the inferior
outcome observed in high-risk vs. standard-risk patients (48, 58).
However, it should be noted that high-risk patients require highly
intensive regimens in order to achieve a proper level of MRD
negativity (47, 52, 55).
FUTURE PERSPECTIVES
Is MRD a Surrogate Endpoint for Drug
Approval?
Improving OS and quality of life is the final aim of MM
treatment. In the past years, the PFS endpoint has been
used as a surrogate endpoint for OS to speed up the drug
approval process. However, following the achievement of long-
standing and deep responses (especially in NDMM patients),
PFS is inappropriately becoming a late endpoint. MRD is
considered the best candidate as a PFS/OS surrogate marker
for provisional drug approval by regulatory agencies. Indeed,
ClonoSEQ R© Assay is now authorized by FDA (66) and MRD
negativity with a sensitivity of 10−5 is the most common
primary endpoint of new clinical trials designed for NDMM
patients. However, as discussed above, continuous efforts should
be exterted to define the optimal sensitivity cut-off (10−5 vs.
10−6), the timing of evaluation and the need for a sustained
MRD negativity. Moreover, safety should be closely addressed,
as it was demonstrated by higher MRD (13.4 vs. 1%) but worse
OS rates (HR 2.03, 95% CI 1.04–3.94) in the experimental
arm of the BELLINI trial (M14-031) comparing venetoclax-Vd
vs. Vd (67, 68). Moreover, in some settings, the correlation
between MRD negativity rates and PFS improvement could
be less clear because of technical pitfalls (e.g., early MRD
evaluation after myelosuppressive treatments in hypocellular
bone marrows).
How to Address Spatial Heterogeneity?
MM is a spatially heterogeneous disease and simultaneous MRD
negativization inside and outside the bone marrow showed
synergistic predictive values (28).
Moreover, MRD analysis within the bone marrow is done
on bone marrow aspirates coming from a single random site
and, in some patients, MM cells show a patchy infiltration (69).
To overcome this issue and to possibly link the information
on residual disease coming from both bone marrow and
extramedullary sites, liquid biopsy approaches are beginning
to emerge. Currently under exploration are the detections at
high sensitivity levels of circulating tumor DNA (70), circulating
plasma cells (71), and M protein peptides (72–74). The further
optimization of the available techniques will be essential for their
future success.
As an example, applying the ClonoSEQ R© assay to peripheral
blood ctDNA and paired BM samples, Mazzotti et al. showed that
residual disease in the peripheral blood was undetectable in 69%
of patients with concurrent MRD-positive bone marrow samples
(70). This was mainly due to an insufficient sensibility to detect
specific Ig gene rearrangements in the peripheral blood when
disease burden was low in the BM (70), underlying the need to
improve the technique before we can routinely exploit peripheral
blood to monitor MM burden.
MRD-Driven Trials
MRD has not yet entered the clinical practice, but it represents
an attractive tool to potentially guide treatment choices. To
address this hypothesis, many MRD-driven trials are beginning
to explore treatment intensification in MRD-positive patients
after standard treatment (e.g., NCT03901963) or treatment
deintensification in sustained MRD-negative patients (e.g.,
NCT03710603). Ongoing and future MRD-driven trials will
contribute to solve the unanswered question: is it recommended
to evaluate other induction cycles until the achievement of MRD
negativity in patients who are MRD-positive after 4 induction
cycles? Can we perform post-transplant consolidation on the
basis of MRD status? Can we stop maintenance after 1 year of
sustained MRD negativity?
Ongoing and future clinical trials will evaluate the definition
and the role of sustained MRD-negativity in treatment decision-
making. On the one hand, the achievement of a MRD-
negative status does not necessarily mean that treatment
should be stopped. Indeed, it should be noted that what we
define as “MRD-negative” is a MRD undetectable with the
current techniques, each one of them having a sensitivity
limit. This means that we are not sure that the disease is
eradicated even in MRD-negative cases. On the other hand,
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the achievement of a MRD-positive status after treatment
brings the question of whether it is necessary to change
treatment, improving the depth of response. However, before
developing response-adjusted treatment strategies based on
MRD status—either intensifying/changing treatment for MRD-
positive patients or de-escalating treatment for MRD-negative
patients—we need to understand if sustained MRD negativity
should be the treatment goal and to define the most
appropriate timepoint for its evaluation (after 1 year or after
more years).
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